Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasm, Residual 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Leukemia 1Hypertension, Pulmonary 1

Interventions

Peripheral Blood Stem Cell Transplantation 26Rituximab 20Cyclophosphamide 18fludarabine phosphate 17Mycophenolic Acid 16Tacrolimus 14Cyclosporine 14Whole-Body Irradiation 12Filgrastim 11Therapeutics 10Psychiatric Rehabilitation 10Flow Cytometry 10Etoposide 10Radiotherapy 8Polymerase Chain Reaction 8Methotrexate 8Busulfan 8Methylprednisolone 7Antilymphocyte Serum 7Cladribine 6immunotoxin HA22 5Lenalidomide 5obinutuzumab 4Vorinostat 4Vemurafenib 4Ondansetron 4Melphalan 4Granulocyte Colony-Stimulating Factor 4Dexamethasone 4Cord Blood Stem Cell Transplantation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Hairy Cell × Caves × Other hematologic neoplasm × Clear all
NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡